Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), a biopharmaceutical firm dedicated to developing therapies for rare diseases, has announced its participation in the Barclays 28th Annual Global Healthcare Conference. Scheduled for March 10, 2026, the event will feature a presentation by Rich Daly, the Company’s President and CEO, along with other management team members. The presentation is set for 3:30 PM ET, and those interested can access the live webcast on Catalyst’s website, where a replay will be available for at least 30 days post-event.

Catalyst Pharmaceuticals has built a reputation for successfully in-licensing and commercializing innovative treatments aimed at improving patient lives, especially for those with challenging medical conditions. The Company prioritizes patient care and accessibility, providing a range of support services to ensure patients can access the necessary treatments effectively.

Headquartered in Coral Gables, Florida, Catalyst has gained recognition for its rapid growth and success in the biopharmaceutical landscape. In 2023, 2024, and 2025, the Company was listed as one of America’s Most Successful Companies by Forbes and was included in the 2025 Deloitte Technology Fast 500™ list among North America’s Fastest-Growing Companies.

Catalyst maintains a strong U.S. presence as the core of its commercial strategy while exploring potential avenues for global expansion. However, the Company cautions that forward-looking statements in its communications may be subject to significant risks and uncertainties that could affect future results. Interested parties can find more information on Catalyst’s developments and filings with the U.S. Securities and Exchange Commission (SEC) by visiting their website or requesting details directly from the Company.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), a biopharmaceutical company focused on rare diseases, is gearing up for participation in the Barclays 28th Annual Global Healthcare Conference on March 10, 2026. This event presents a strategic opportunity for the company to showcase its strengths and future direction, particularly its commitment to develop innovative therapies for underserved patient populations.

Investors should note Catalyst's solid performance track record, with the company being recognized by Forbes as one of America's Most Successful Companies from 2023 to 2025. This reputation is bolstered by its presence on the Deloitte Technology Fast 500™ list, signifying rapid growth. However, potential investors need to remain cautious; a review of its SEC filings is advised to understand inherent risks associated with biopharmaceuticals, which can include regulatory hurdles, market competition, and clinical trial outcomes.

The firm's concentration on in-licensing and accessibility to its therapies ensures that it is not only meeting existing patient needs but is also well-positioned for future growth. By prioritizing patient care, Catalyst has secured a reputation for its seamless access and ongoing support services. This aspect should resonate positively with investors, as patient satisfaction often translates into sustained revenue growth.

As the presentation approaches, monitoring any insights into Catalyst's pipeline advancements or strategic initiatives will be key. A focus on its ability to leverage partnerships for expansion could also indicate future revenue streams. Thus, maintaining a close watch on the company's communications post-event will be essential in assessing investment viability.

In summary, Catalyst Pharmaceuticals represents a compelling option within the healthcare space, with its strong growth profile and commitment to rare diseases. However, diligence in evaluating risk factors remains crucial for informed investment decisions.